Solve Therapeutics Secures $120 Million to Advance Next-Generation ADC Platform for Solid Tumors
核心洞察
Solve Therapeutics (搜索) raised $120 million in an oversubscribed financing round led by Yosemite (搜索) to accelerate development of its clinical-stage ADC pipeline featuring proprietary CloakLink™ linker technology.
The company's lead programs SLV-154 and SLV-324 are currently in Phase 1 clinical trials for solid tumors, with funding supporting completion of Phase 1b studies and operational expansion.
Solve's CloakLink™ platform addresses traditional ADC limitations by increasing stability and decreasing hydrophobicity, potentially enabling improved therapeutic indices and reduced toxicity.
Solve Therapeutics (搜索), a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumor malignancies, announced it has raised $120 million in an oversubscribed and upsized financing round. The funding will accelerate development of the company's clinical pipeline and proprietary CloakLink™ linker platform technology.
The round was led by Yosemite (搜索), with participation from new investors including Abingworth (搜索), Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co. (搜索), and SymBiosis, alongside all existing investors. This latest funding follows a $75 million financing completed in December 2024, bringing Solve's total capital raised to $321 million since formation.
Addressing ADC Limitations with Novel Linker Technology
Solve Therapeutics (搜索) was founded to develop next-generation ADCs capable of addressing unique challenges presented by solid tumors. Traditional ADCs often face limitations related to payload hydrophobicity, including sub-optimal pharmacokinetics and plasma stability, which can compromise safety and efficacy.
The company's proprietary CloakLink™ technology was engineered to overcome these barriers by increasing ADC stability and decreasing ADC hydrophobicity across a broad range of drug-to-antibody ratios. According to CEO Dave Johnson, the ADCs built on this technology should stay fully intact when circulating through the bloodstream and only activate after reaching a tumor, enabling more precise delivery of toxic payloads.
"The result is a class of ADCs with improved pharmacokinetics, enhanced plasma stability, and reduced toxicity, enabling improved therapeutic indices and overall performance," the company stated.
Clinical Pipeline Progress
The company's lead programs, SLV-154 and SLV-324, are currently in Phase 1 clinical trials in patients with solid tumors. Both utilize the CloakLink™ platform and targeting antibodies that are specifically engineered for superior ADC performance. The ADCs are paired with novel diagnostic approaches to enable precision patient selection.
SLV-154 is being tested against head and neck cancer, non-small cell as well as small cell lung cancers, and bladder tumors, among others. The company has not yet disclosed which cancers SLV-324 will target.
Johnson indicated that the trials are enrolling ahead of schedule, stating: "We're excited about the progress across our clinical programs and look forward to sharing more as the data emerges." The data generated so far, while early, are "validating and consistent" with what the company observed in preclinical testing.
Strategic Investment and Leadership
The new funding will support the completion of Phase 1b studies for both programs and expand the company's operational capabilities as it advances toward later-stage clinical development.
"We're thrilled to partner with an outstanding syndicate of investors who share our vision for developing best-in-class ADCs," said Dave Johnson, CEO & Co-Founder of Solve Therapeutics (搜索). "Since founding the company, we've built a differentiated platform that combines next-generation ADC engineering, a superior hydrophilic linker system, and novel patient-selection diagnostics."
Dan McHugh, Investor at Yosemite (搜索) and Solve Therapeutics (搜索) board member, commented: "Solve is the next wave of ADC innovation. By integrating therapeutic development with a novel diagnostic platform, Solve is pushing the boundaries of precision oncology and enabling a more personalized, effective approach to cancer care."
Company Background and Competitive Positioning
Founded by leaders behind VelosBio (搜索) (acquired by Merck) and Acerta Pharma (acquired by AstraZeneca), Solve Therapeutics (搜索) is applying decades of combined oncology and ADC expertise to build a pipeline of pioneering therapeutics and diagnostics targeting solid tumors with high unmet need.
Johnson emphasized that what should help Solve stand out is the way it's specifically optimizing each component — antibody, linker and toxin — to "work together." The company is aiming its ADCs at a range of solid tumors with "high unmet need," positioning itself in the competitive ADC landscape where several companies are working on new linkers or tinkering with ADCs in other ways to boost their effectiveness and safety.